ESPERION THERAPEUTICS

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

20 May 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 May 2024 15:00:00 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2024 Financial Results

07 May 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming May Investor Conferences

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2024 Financial Results on May 7

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

07 Apr 2024 13:45:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ESPERION THERAPEUTICS INC. - COMMON STOCK

04 Apr 2024 08:45:59 By NetDania Notify

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

25 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

22 Mar 2024 14:10:20 By Nasdaq GlobeNewswire

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

22 Mar 2024 10:04:39 By Nasdaq GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

27 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

01 Feb 2024 13:00:00 By Nasdaq GlobeNewswire

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

23 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

18 Jan 2024 20:15:58 By Nasdaq GlobeNewswire

Esperion Announces Proposed Public Offering of Common Stock

18 Jan 2024 15:00:00 By Nasdaq GlobeNewswire